|
Profile |
Business Strategy |
Competitive Positioning |
History |
People |
Facilities
|
|
Management 
Advisory Board
|
|
|
|
Prof. Inger Sandlie is Professor in the
Department of Molecular Biosciences (IMBV) at the University of Oslo, Norway. Inger
trained in Biochemistry, got her PhD at the University of
Bergen on a problem related to DNA repair, and then did a post doc at Johns
Hopkins University in Maryland, USA- still on DNA repair. After her return to
Norway, she focused on antibody engineering. She worked at The Norwegian Radium hospital
for three years before she
joined the Faculty of the Biology Department in 1988, and IMBV in 2005. Her
main published scientific achievements concern the function of the Fc region of
antibodies, and in particular the role of the hinge region and isotype specific
amino acids for structure and function of IgG and IgD, the molecular requirements
for polymerisation of IgA and IgM, as well as the development of
"Troybodies".
Administration:
Member of and leader of
Program for cell and gene technology (1997-2001), and FUGE, The Norwegian
Research Council (05-), Member of The
National Bioethics Committee, 1999-2000 and the Research Fund for the Norwegian
Radium Hospital (02-).
Awards:
Innovation prize from Forny in 1996 and Medinnova in 2003. Member of The
Norwegian Acadamy of Sciences and Letters from 2002.
|
|
Prof. Peter Hudson,
is Deputy CEO and Scientific Director of the CRC for Diagnostics and
is Research Director for Diagnostics and Biopharmaceuticals at CSIRO Molecular
and Health Technologies, leading research groups in Australia
at Parkville (Melbourne), Adelaide and Brisbane.
Peter was elected a Fellow of the Australian Academy of Technological
Sciences in 2002 and in 1997 was awarded both the AMRAD Biotech
Medal and shared the CSIRO Chairman's Medal. Peter has held an Adjunct
Professorship in Biochemistry by La Trobe University since 1993 Prof.
Hudson has led the CSIRO Program for Protein Engineering since 1992 for the
design of improved antibodies and development of in vitro selection
technologies, which supersede hybridoma technology for antibody production.
Recent achievements include the characterisation of several antibody (scFv)
structures and the design of novel dimeric antibodies (diabodies) with
applications for tumour imaging, diagnosis and therapy.
|
|
Prof.
Lorenz Trümper
is Professor of Internal Medicine and Chairman of the Department of Hematology
and Oncology at the Georg August University of Göttingen, Germany. He received
his M.D. degree from Freiburg University, worked as a clinical research fellow
at the University of Toronto's Princess Margaret Hospital and completed his
M.D./PH.D. thesis on molecular aspects of Hodgkin's disease at Saarland
University. As a member of the steering board of the German lymphoma trial
boards, he is actively involved in clinical research in malignant lymphoma.
|
|
Prof. Arthur M. Mercurio received his B.S. in biochemistry magna cum laude
from Rutgers
University in 1975 and a Ph.D. in cell
biology from Columbia University in 1981. He was a Postdoctoral Fellow in the Center for
Cancer Research at M.I.T.
from 1981-1985. In 1986, he joined the
faculty at Harvard Medical School and the Beth Israel Deaconess Medical
Center. He was the Director of the
Division of Cancer Biology and Angiogenesis at BIDMC until 2005 when he became
Professor and Vice Chairman of the Department of Cancer Biology at the
University of Massachusetts Medical School and Associate Director for Basic Research
of the UMass Cancer
Center. Dr. Mercurio is a recipient of the American Cancer Society Junior
Faculty and Faculty Research Awards, and he is an Honorary Professor of Tumor
Biology at the University of Copenhagen. He has served on numerous NIH committees and editorial
boards. Professor
Mercurio's research is focused on understanding mechanisms involved in the
genesis of invasive carcinomas and the progression to metastatic disease.
|
|
Prof. Rolf Seljelid received his MD at the University of Bergen,
Norway, in 1959, and his PhD from The Karolinska Institute, Stockholm, Sweden,
in 1966. After activities at the Karolinska Institute and the Rockefeller
University, NY, he became Professor and Chairman of the Dept. of
Experimental Pathology and Anatomy of the Tromsø University Medical School,
Tromsø, Norway from 1971-2004. Among many other responsibilities, he was member
of the Board of Directors of the Tromsø University (1977-1980), Chairman of the
Norwegian National Scientific Counsil (1996-2004), Chairman of the board of the
Norwegian Institute for Gene Ecology (1997-2004). Since 2004, Rolf Seljelid is
Professor Emeritus at the Tromsø University. He is member of the Royal Swedish
Society of Science, of the Royal Norwegian Society of Science, and the
Norwegian Academy of Science and Humanities, and the Norwegian Academia
Borealis. He was awarded with the Olav og Erna Aakre Prize for Oustanding
Cancer Research in 1988. Prof. Seljelid published around 200 scientific
articles.
|
|
Dr. Jürgen Krauss studied Medicine at the Universities of Mainz and Berlin, Germany. After receiving his M.D. degree from the University of Berlin, Dr. Krauss has specialized in Internal Medicine and Medical Oncology at the Universities of the Saarland and Duisburg-Essen, respectively. His clinical work at the University of Duisburg Essen, Department of Medical Oncology and Cancer Research, is currently focused on the implementation of phase I/II trials with novel anti-cancer therapeutics.
Jürgen has a strong scientific background in Antibody Engineering and development of recombinant antibodies and derivatives for cancer therapy. After successful generation of a chimerized anti-CD30 antibody for his doctoral thesis, Dr. Krauss has created viable bispecific antibody fragments with anti-CD16/CD30 specificity in collaborative work between the University of the Saarland and the German Cancer Research Center Heidelberg. From 2000-2003 Jürgen joined Dr. Rybak.s laboratory at the National Cancer Institute, USA, where he designed and produced novel thermostable antibody fragments and derived fusion proteins using ribonucleases (RNases) as potent yet presumably well tolerable effector moieties. Research efforts of Dr. Krauss. newly founded research group at the University of Duisburg-Essen in 2004 are focused on the clinical development of immunoRNases for cancer therapy. Furthermore, Juergen.s group is working on the development of also non-RNase based immunotherapeutics with pro-apoptotic properties. To efficiently translate basic research into successful clinical applications, Dr. Krauss. group closely collaborates with a variety of both academic and industrial partners.
|
|
